Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Pearl Toh, 11 May 2020
Adding trastuzumab to a chemotherapy backbone of carboplatin and paclitaxel led to sustained survival benefit in patients with recurrent/advanced, HER2-positive uterine serous carcinoma compared with chemotherapy alone, according to an updated survival analysis presented at SGO 2020 Meeting.
Dr Margaret Shi, 27 Feb 2020

Olaparib, a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, represents a paradigm shift in management of metastatic castration-resistant prostate cancer (mCRPC) in view of the promising results shown in recent trials, said Professor Przemyslaw Twardowski of John Wayne Cancer Institute of Santa Monica, California, US, who spoke at the Uro-Oncology Asia 2020 conference.

HIỆU QUẢ VÀ TÍNH AN TOÀN CỦA PEMBROLIZUMAB TRONG UNG THƯ BIỂU MÔ TẾ BÀO GAN NGUYÊN PHÁT TIẾN TRIỂN SAU ĐIỀU TRỊ VỚI SORAFENIB

07 May 2020
Ung thư biểu mô tế bào gan nguyên phát (UTBMTBG) là nguyên nhân gây tử vong do ung thư hàng đầu trên thế giới. Mặc dù đã có những lựa chọn điều trị triệt để cho bệnh nhân giai đoạn sớm như phẫu thuật cắt gan, ghép gan hoặc phá hủy khối u, nhưng hầu hết bệnh nhân thường được chẩn đoán ở giai đoạn bệnh tiến triển, không thể phẫu thuật được.(1) 
UTBMTBG giai đoạn tiến triển ít có lựa chọn điều trị. Một số liệu pháp có sẵn như sorafenib và các thuốc ức chế tyrosin kinase khác đã cho thấy có liên quan đến độc tính mặc dù có cải thiện thêm về sống còn.(2) 
Pembrolizumab là một kháng thể đơn dòng kháng PD-1, có hoạt tính kháng bướu, được chứng minh hiệu quả trong nhiều bệnh lý ung thư khác nhau như: u hắc tố, ung thư phổi không tế bào nhỏ, ung thư đầu cổ…với hồ sơ an toàn có thể quản lý được.(3) Vì vậy, vai trò của pembrolizumab cũng đã được đánh giá trên bệnh nhân UTBMTBG qua nghiên cứu KEYNOTE-224.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Vietnam digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Pearl Toh, 11 May 2020
Adding trastuzumab to a chemotherapy backbone of carboplatin and paclitaxel led to sustained survival benefit in patients with recurrent/advanced, HER2-positive uterine serous carcinoma compared with chemotherapy alone, according to an updated survival analysis presented at SGO 2020 Meeting.
Dr Margaret Shi, 27 Feb 2020

Olaparib, a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, represents a paradigm shift in management of metastatic castration-resistant prostate cancer (mCRPC) in view of the promising results shown in recent trials, said Professor Przemyslaw Twardowski of John Wayne Cancer Institute of Santa Monica, California, US, who spoke at the Uro-Oncology Asia 2020 conference.